CAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

被引：5
|
作者：
Messori, Andrea [1 ]
Damuzzo, Vera [2 ]
Leonardi, Luca [3 ]
Agnoletto, Laura [3 ]
Chiumente, Marco [3 ]
Mengato, Daniele [3 ]
机构：
[1] Reg Hlth Serv, HTA Unit, Via San Salvi 12, I-50135 Florence, Italy
[2] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Sch Hosp Pharm, Padua, Italy
[3] Italian Soc Clin Pharm & Therapeut, Sci Direct, Milan, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷 / 07期
关键词：
TIME;
D O I：
10.1016/j.clml.2020.02.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：490 / 491
页数：2
相关论文
共 50 条
  • [21] Choosing a CAR for Relapsed/Refractory Large B-cell Lymphoma
    Abramson, Jeremy S.
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (10): : 621 - 622
  • [22] Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
    Paillassa, Jerome
    Safa, Firas
    LEUKEMIA RESEARCH REPORTS, 2022, 17
  • [23] The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma
    Lutfi, Forat
    Kansagra, Ankit
    Ali, Moaath Mustafa
    Bukhari, Ali
    Siglin, Jonathan
    Yan, Jingsheng
    Samanta, Santanu
    Holtzman, Noa G.
    Gottlieb, David
    Kim, Dong Won
    Lee, Seung-Tae
    Kocoglu, Mehmet Hakan
    Yared, Jean A.
    Hardy, Nancy M.
    Molitoris, Jason
    Mohindra, Pranshu
    Rapoport, Aaron P.
    Dahiya, Saurabh
    BLOOD, 2020, 136
  • [24] Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Juarez-Salcedo, Luis Miguel
    Nimkar, Santosh
    Corazon, Ana Maria
    Dalia, Samir
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
  • [25] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
    Lu, Q.
    Huang, H.
    Tang, S.
    Wang, Y.
    Yang, D-H
    DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
  • [26] CAR-T Therapy in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: Real World Outcomes Based on Tumor Biology
    Brinkman, Luke
    Wagner, Charlotte B.
    Ying, Jian
    Fraga, Martina
    Marini, Bernard L.
    Scappaticci, Gianni Bruno
    Ptachcinski, Jonathan
    Patel, Sagar S.
    BLOOD, 2022, 140 : 9546 - 9547
  • [27] Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Dickinson, Michael J.
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Sureda, Anna
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Dixon, Mark
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    Trney, Marek
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24): : 2220 - 2231
  • [28] Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
    Epperla, Narendranath
    Lucero, Melanie
    Bailey, Tom
    Mirams, Laura
    Cheung, Jolenta
    Amet, Mona
    Milligan, Gary
    Chen, Lei
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [29] CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma
    Gideon, Jacklyn
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2022, 26 (06) : 597 - 601
  • [30] ROLE OF CAR-T CELLS THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Sen, P.
    Saadeh, B.
    Loh, E.
    VALUE IN HEALTH, 2019, 22 : S440 - S441
12345